Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2022

View Archived Issues

TLR2/6 agonist AXA-042 shows antitumor activity and tolerability in vivo

Plexium compound shows the promise of BRD4 degradation for prostate cancer

Guangzhou Fermion Technology patents new CDK7 inhibitors

CSPC Zhongqi Pharmaceutical Technology divulges salts of tyrosine kinase inhibitors

Medshine Discovery identifies new CSF-1R inhibitors

New P2X3 antagonists presented by National Institute of Pharmaceutical R&D

Shanghai Visonpharma synthesizes new TLR7 agonists

Ono establishes collaborations to discover small molecules targeting GPCRs in metabolic disease

TAK-676 shows antitumor efficacy as monotherapy or in combination

MJFF grant supports Neuropore's development of TLR2 antagonist for Parkinson's disease

AUR-103 in combination with azacytidine and bortezomib for myeloma and leukemia treatment

Discovery of novel BACE1 inhibitor with optimal balance of potency and drug-like properties

Testing viruses, vaccines, to increase solid tumor CAR T persistence

Sionna closes series B financing to support development of CFTR modulators

Antengene presents anti-CLDN18.2 ATG-022 for the treatment of gastric cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...